Benjamin F. Edwards & Company, Inc. Clovis Oncology, Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$2.7 - $4.76 $126,360 - $222,768	-46,800 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$4.06 - $5.8 $173,767 - $248,240	-42,800 Reduced 47.77%	46,800 $209,000
Q2 2021 Aug 11, 2021	SELL	$5.02 - $7.05 $27,007 - $37,929	-5,380 Reduced 5.66%	89,600 $520,000
Q1 2021 May 14, 2021	BUY	$4.81 - $10.34 $456,853 - $982,093	94,980 New	94,980 $667,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.